High-Dose Chemotherapy plus Hematopoietic Stem-Cell Rescue for Metastatic Breast Cancer

2000 ◽  
Vol 343 (6) ◽  
pp. 439-441 ◽  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Metastatic Breast Cancer ◽  
Hematopoietic Stem Cell ◽  
Metastatic Breast ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Rescue

scholarly journals High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: Experience in California

2000 ◽  
Vol 6 (5) ◽  
pp. 496-505 ◽  
Author(s):  
Lloyd E. Damon ◽  
Wendy W. Hu ◽  
Keith E. Stockerl-Goldstein ◽  
Karl G. Blume ◽  
Jeffrey L. Wolf ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Rescue ◽  
Cancer Experience

scholarly journals High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Transplantation in Metastatic Breast Cancer: Overview of Six Randomized Trials

2011 ◽  
Vol 29 (24) ◽  
pp. 3224-3231 ◽  
Author(s):  
Donald A. Berry ◽  
Naoto T. Ueno ◽  
Marcella M. Johnson ◽  
Xiudong Lei ◽  
Jean Caputo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Stem Cell ◽  
Metastatic Breast Cancer ◽  
Randomized Trials ◽  
Metastatic Breast ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Hematopoietic Stem ◽  
High Doses

Purpose High doses of effective chemotherapy are compelling if they can be delivered safely. Substantial interest in supporting high-dose chemotherapy with bone marrow or autologous hematopoietic stem-cell transplantation in the 1980s and 1990s led to the initiation of randomized trials to evaluate its effect in the treatment of metastatic breast cancer. Methods We identified six randomized trials in metastatic breast cancer that evaluated high doses of chemotherapy with transplant support versus a control regimen without stem-cell support. We assembled a single database containing individual patient information from these trials. The primary analysis of overall survival was a log-rank test comparing high dose versus control. We also used Cox proportional hazards regression, adjusting for known covariates. We addressed potential treatment differences within subsets of patients. Results The effect of high-dose chemotherapy on overall survival was not statistically different (median, 2.16 v 2.02 years; P = .08). A statistically significant advantage in progression-free survival (median, 0.91 v 0.69 years) did not translate into survival benefit. Subset analyses found little evidence that there are groups of patients who might benefit from high-dose chemotherapy with hematopoietic support. Conclusion Overall survival of patients with metastatic breast cancer in the six randomized trials was not significantly improved by high-dose chemotherapy; any benefit from high doses was small. No identifiable subset of patients seems to benefit from high-dose chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document